Nasdaq.comUS
MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L)…